Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.52 |
| ▸ | CDK2 | P24941 | 9/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13305601 | 0.89 | CDK2 (0.54) | GSK3BCDK2CCNE1NPC1RAB9A | |
| SCHEMBL12953028 | 0.88 | CDK2 (0.68) | GSK3BCDK2CCNE1 | |
| SCHEMBL13146084 | 0.84 | GSK3B (0.49) | GSK3BCDK2CCNE1NPC1RAB9A | |
| SCHEMBL13304888 | 0.83 | CDK2 (0.54) | GSK3BCDK2CCNE1NPC1RAB9A | |
| SCHEMBL13146184 | 0.81 | GSK3B (0.50) | GSK3BCDK2CCNE1NPC1RAB9A | |
| SCHEMBL13146048 | 0.81 | GSK3B (0.77) | GSK3BCDK2CCNE1 | |
| SCHEMBL13305042 | 0.81 | HRH4 (0.50) | GSK3BCDK2CCNE1 | |
| SCHEMBL13304953 | 0.81 | GSK3B (0.49) | GSK3BCDK2CCNE1NPC1RAB9A | |
| SCHEMBL13304616 | 0.78 | CDK2 (0.49) | GSK3BCDK2CCNE1NPC1RAB9A | |
| SCHEMBL13305033 | 0.78 | CDK2 (0.58) | GSK3BCDK2CCNE1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |